Area of research
Biomaterials · Surgery
Research interest
Research topics from publications: Progress on liposome delivery systems in the treatment of bladder cancer; Recent advances in bladder cancer stem cells (BCSCs): A descriptive review of emerging therapeutic targets. Representative work: liposomal therapies are also discussed, demonstrating that liposomal formulations have great potential application value in the treatment of BC owing to their superior bioavailability, stability, and targeting and minimal adverse effects Bladder cancer (BC) is the most common malignancy of the urinary system, characterized by high recurrence due to limited specificity and efficacy of current therapies. Bladder cancer stem cells (BCSCs), a distinct subpopulation within BC, exhibit self-renewal, tumorigenicity, and resistance to conventional treatments, playing a critical role in BC initiation, progression, metastasis, and recurrence. This study reviews the origins, biomarkers, and therapeutic potential of BCSCs, emphasizing emerging strategies targeting these cells. BCSCs can arise from urothelial stem cells or differentiated cells, with markers such as CD44, EZH2, ALDH1A1, and SOX2 enabling their identification. Aberrant act